Skip to main content
Sign In

University of Colorado Denver


Komal Raina, PhD

Assistant Research Professor, Department of Pharmaceutical Sciences

Photo of Dr. Komal Raina

Mailing address:

University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Mail Stop C238
12850 E. Montview Blvd. V20-2430
Aurora, CO 80045

Office Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Second Floor
Room 2430

Lab Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Second Floor
Room 2430



  • Associate Member, University of Colorado Cancer Center

Training and Education:

  • BPharm- Hamdard University, New Delhi, India
  • MPharm (Pharmaceutics) - UIPS, Chandigarh, India
  • PhD (Pharmaceutics) – Talwar Research Foundation/ Hamdard University, New Delhi, India
  • Postdoctoral fellow- University of Colorado Denver

Research Interests:

In the past, I have been primarily involved in understanding the mechanistic effects of various phytochemicals on cell signaling proteins involved in tumorigenesis and metastasis using in vitro and in vivo pre-clinical cancer models (Prostate, Colon, Bladder and Lung cancer). Lately, my focus has been to examine the effect of cancer stem cell population, its self-renewal and metabolism and associated inflammatory microenvironment components including the microbiome, on epithelial cancer initiation, promotion and progression, under obese conditions.

Representative Publications:

  1. Raina Komal, Singh RP, Agarwal R, and Agarwal C. Oral Grape Seed Extract Inhibits Prostate Tumor Growth and Progression in TRAMP Mice. Cancer Res. 2007; 67:5976-82.
  2. Raina Komal, Marie-José Blouin, Singh RP et al. Dietary Feeding of Silibinin Inhibits Prostate Tumor Growth and Progression in TRAMP Mice. Cancer Res. 2007; 67(22):11083-91.
  3. Raina Komal , Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2008 Aug 15;68(16):6822-30.
  4. Raina Komal, Serkova NJ, Agarwal R. Silibinin Feeding Alters the Metabolic Profile in TRAMP Prostatic Tumors: 1H-NMRS-Based Metabolomics Study. Cancer Res. 2009, 69: 3731-3735. (Journal Priority Report)
  5. Mateen S, Raina Komal, Jain AK, Agarwal C, Chan D, Agarwal R. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics. 2012;7: 1161-72.
  6. Mateen S, Raina Komal, Agarwal C, Chan D, Agarwal R. Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Up-regulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells. J Pharmacol Exp Ther. 2013; 345: 206-214. (Journal Cover Page)
  7. Raina Komal, Ravichandran K, Rajamanickam S, Huber KM, Serkova NJ, Agarwal R. Inositol hexaphosphate inhibits tumor growth, vascularity, and metabolism in TRAMP mice: a multiparametric magnetic resonance study. Cancer Prev. Res. 2013;6(1):40-50. (Journal Cover Page)
  8. Raina Komal, Agarwal C, Wadhwa R, Serkova NJ, Agarwal R. Energy deprivation by silibinin in colorectal cancer cells: A double-edged sword targeting both apoptotic and autophagic machineries. Autophagy. 2013;9(5):697-713.
  9. Jain, AK, Raina Komal, Agarwal R. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in Transgenic Adenocarcinoma of the Mouse Prostate model. Cell Cycle. 2013;12(10):1598-604. doi: 10.4161/cc.2474.
  10. Derry M, Raina Komal, Balaiya V, Jain AK, Shrotriya S, Huber KM, Serkova NJ, Agarwal R, Agarwal C. Grape Seed Extract Efficacy against Azoxymethane-induced Colon Tumorigenesis in A/J Mice: Interlinking miRNA with Cytokine Signaling and Inflammation. Cancer Prev. Res. 2013;6(7):625-33.
  11. Kumar S, Raina Komal, Agarwal C, Agarwal R. Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by modulating interleukin 4/6-mediated survival signals. Oncotargets 2014, in press.